Morgan Cheatham is a Vice President with Bessemer Venture Partners where he leads healthcare and life sciences investments from seed to growth stages. He focuses across the value chain spanning software, therapeutics, services, and diagnostics, to improve patient care from bench to bedside and specializes in applications of computation in biomedicine.

Select investments in his portfolio include Abridge, Hinge Health, Headspace Health (fka Ginger), Subtle Medical, Turquoise Health, Productboard, Plenful, Groups Recover Together, Ansible Health, and FOLX Health, where he serves on the board and previously served as Interim CEO. He was awarded Forbes 30U30 for Venture Capital and the National Venture Capital Association Rising Star Award in 2023.

Morgan is pursuing medical training at The Warren Alpert Medical School of Brown University with a research focus in bioinformatics. His research collaborations include the Shah Lab at the Stanford Institute for Human-Centered AI, where he is investigating the clinical utility and validation of LLMs, and more recently, the Zitnik Lab at the Harvard Department of Biomedical Informatics, where he is interested in investigating questions pertaining to multi-modal phenotyping and therapeutic response prediction. He is also a member of the New England Journal of Medicine Artificial Intelligence Editorial Team. He earned his bachelor of science from Brown University.